A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors

Summary

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in combination with HX008 in patients with EGFR-positive advanced or metastatic solid tumors.

Timeline

Start

2022-06-30

Primary completion

2027-08

Completion

2027-08

Publications

• Ruan DY, Wang FH, Zhou Y, Xiang Y, Lin J, Liu L, Liu P, Tang L, Ma Y, Hou T, Chen Q, Li ZM, Han F, Qu S, Qiu S, Han C, Ma H, Su F, Gao J, Guo Y, Wu Z, Wu HJ, Zhao Y, Fang M, Hu M, Wu Y, Cui S, Li M, Zhao Q, Xu RH. Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma. J Clin Oncol. 2026 Aug 25:JCO2600640. doi: 10.1200/JCO-26-00640. Online ahead of print.

Drugs

Indications